Evidence review

TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping

#peptide#topic
bundle · json · system map · manifest

Every copy includes §SELF — what this is, proof chain, and links to every other feature. No context required.

§SELF — this page explains the system
## §SELF — miscsubjects (paste without context)

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `human_page` — **Human article page**
Rendered article with claims, sources, copy widgets, ask prompts.
- **article slug:** `tb-500-glp1-muscle-loss`
- **contains:** rendered article, copy widgets, claims, sources, ask prompts
- **how to use:** Use Copy for LLM or Copy system map — both paste without context.
- **read:** https://miscsubjects.com/a/tb-500-glp1-muscle-loss

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/tb-500-glp1-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **bundle** — Paste-ready package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/tb-500-glp1-muscle-loss/bundle?format=markdown
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/tb-500-glp1-muscle-loss/prompts
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/tb-500-glp1-muscle-loss/topology

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

*Not medical advice. Tier-honest. Cite claim/source ids.*

What's breaking down if you have GLP-1 muscle loss / sarcopenia

The body is always doing two things at once: breaking down (degeneration) and building back (regeneration). A condition persists when breakdown outruns repair. Most drugs used for symptoms suppress a signal (pain, acid, anxiety, inflammation) without fixing the tissue that caused the signal. Peptides in this ledger are studied for repair pathways: new blood vessels, repair-cell migration, nerve regrowth, gut lining, neural connections. This article maps one compound through that frame — what it is, how it is proposed to work, what evidence exists, and what people report.

This topic: TB-500 (thymosin beta-4) is studied for repair-cell migration and actin regulation — cells that need to reach an injury and rebuild structure. That is regeneration: move repair machinery to the damage.

Why TB-500 might help you

  1. You are reading about GLP-1 muscle loss / sarcopenia — what breaks down matters before any compound name.
  2. What keeps failing: Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.
  3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
  4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

Why GLP-1 agonists (class) matters for you

  1. Drug: GLP-1 agonists (class)
  2. What it does: Metabolic benefit vs gut slowing / muscle loss tradeoffs at rapid weight loss.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

Why PPIs (omeprazole, etc.) matters for you

  1. Drug: PPIs (omeprazole, etc.)
  2. What it does: Acid suppression; long-term mucosal and nutrient consequences.
  3. Therefore for you: state whether this drug reduces load, suppresses a signal, or supports metabolism — and whether that helps or trades off repair for your condition.

How these fit together

Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.

  • TB-500 → inflammation clearance / repair-cell migration

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

  • Scientific sources catalogued (PubMed, trials, reviews): 8
  • Claims tagged human evidence: 7
  • Claims tagged preclinical (animal/lab): 1
  • Claims tagged anecdotal: 13
  • Reddit posts catalogued: 10
  • X posts catalogued: 2
  • Other anecdote sources (YouTube, Instagram, etc.): 0
  • Total sources in chain: 22

Quantified confidence (this ledger): 0.95 / 1.00 — moderate — human claims present in ledger

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonist Effects (source s1)

Summarizes DXA data from major GLP-1 trials on lean mass fractions of weight loss.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

TB4 and TB-500 Peptide Therapy | What to Know in 2026 (source s2)

Reviews human trial safety data and mechanistic actions of thymosin beta-4/TB-500.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Thymosin beta4 accelerates wound healing (source s3)

1999 rat study establishing preclinical wound healing acceleration.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians (source s4)

2026 narrative review noting preclinical benefits of TB-500 for tissue repair but lack of human orthopaedic evidence; no specific GLP-1 mention but relevant to muscle contexts.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

TB-500 with GLP-1: Best Protocol (source s5)

Clinic article from Apr 2026 detailing protocol for combining TB-500 with GLP-1 agonists specifically for musculoskeletal recovery and lean mass support during weight loss.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

Peptide Stacking for Muscle Preservation on GLP-1s: The Complete Protocol (source s6)

Apr 2026 blog on stacking TB-500 (among others) to counteract muscle loss from GLP-1 weight loss drugs via satellite cell activation and anti-apoptosis effects.

Evidence type: Published research.

The Wolverine Peptide Stack: A Clinical Guide for Injury Recovery, GH Restoration, and Muscle Preservation on GLP-1s (source s9)

Clinic guide explicitly recommends TB-500 (as part of Wolverine stack with BPC-157 etc.) to help preserve lean muscle mass for patients on GLP-1 agonists like semaglutide/tirzepatide, citing muscle loss concerns and synergistic tissue support.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

GLP-1 | Delaware Integrative Medicine (source s10)

Integrative medicine site promotes combining their GLP-1 peptide therapy with TB-500 (Thymosin Beta-4) and BPC-157 specifically for muscle repair, growth, and preserving muscle mass during weight loss, contrasting with synthetic GLP-1s that cause muscle loss.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

What people say on Reddit

Thoughts on BPC-157? — Reddit, r/crossfit (source s7)

Reddit anecdote in context of peptides, with mentions of Ozempic/GLP-1 users seeking recovery aids.

Peptide stacking cheat sheet. What goes together and why — Reddit, r/NTNPerformance (source s12)

Discusses stacking TB-500/BPC with GLP-1s like semaglutide/tirzepatide for muscle preservation during weight loss; anecdotal community advice on protocols (anecdotal, not advice).

Peptides for faster recovery — Reddit, r/workout (source s13)

Users discuss TB-500 with semaglutide noting muscle loss risks and recovery anecdotes (anecdotal, not advice).

microdosing GLP-1s for maintenance and what I'm seeing ... — Reddit, r/GLP1microdosing (source s14)

Mentions TB-500 alongside GLP-1 microdosing for muscle/joint support; anecdotal dosing discussion (anecdotal, not advice).

💪 The Muscle-Saving Stack for GLP-1 Users (Don’t Let Fat Loss Kill Your Gains) — Reddit, r/BodyHackGuide (source s15)

User shares personal stack including TB-500 with GLP-1s for muscle preservation; anecdotal results like maintained strength (anecdotal, not advice).

Semaglutide reduces muscle mass? — Reddit, r/Peptides (source s16)

Thread on semaglutide muscle loss concerns, with some mentions of peptides like TB-500 in comments for mitigation (anecdotal).

Documenting My ACLR + Meniscus Repair Journey – Trying the “Wolverine Stack” (BPC-157 + TB-500) — Reddit, r/ACL (source s17)

User documenting use of BPC-157 + TB-500 (Wolverine Stack) for ACL/meniscus recovery while on or considering GLP-1 context; anecdotal recovery protocol 5 days on/2 off.

To everyone freaking out about “muscle wasting”... — Reddit, r/tirzepatidecompound (source s18)

Discussion on muscle loss from tirzepatide/GLP-1; user mentions stacking with BPC-157/TB-500 for muscle preservation; anecdotal experiences of strength loss and recovery via training/protein.

peptides cheatsheet — Reddit, r/Biohackers (source s19)

Peptide cheat sheet including TB-500 for muscle repair/inflammation with GLP-1s like semaglutide/tirzepatide/retatrutide; anecdotal stacking protocols and dosing examples labeled as educational.

Peptides are all hype? — Reddit, r/crossfit (source s20)

User trial of TB-500/BPC-157 for 90 days in CrossFit context, noting potential muscle loss concerns with GLP-1s like semaglutide; mixed anecdotal outcomes on peptides.

What people say on X

peptides stack post — X (source s21)

X post on peptide stacks pairing TB-500 with GLP-1s (semaglutide/tirzepatide) for fat loss and muscle recovery; anecdotal benefits listed.

Best Peptide Stack for Fat Loss & Muscle Retention — X (source s22)

X post recommending BPC-157 + TB-500 stack with GLP-1s for muscle retention during fat loss; dosing not specified, anecdotal research use.

What we do not know

  1. No human trials examine TB-500 with GLP-1 agonists or for lean mass preservation during GLP-1 therapy.

Safety and limits

  1. Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.

Peptide components (collapsible embeds)

TB-500: Thymosin Beta-4 · inflammation clearance / repair-cell migration · tb-500
{
  "peptide": "tb-500",
  "regenerative_layer": "inflammation clearance / repair-cell migration",
  "targets_this_degeneration": "Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.",
  "proposed_regeneration": "Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.",
  "evidence_in_ledger": {
    "human_claims": 14,
    "preclinical_claims": 4,
    "anecdote_claims": 74,
    "studies_catalogued": 25
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/tb-500"
}

Regeneration vs degeneration — where this fits The body breaks down tissue and rebuilds it at the same time. When breakdown stays ahead of repair, injury or disease persists. Most drugs block signals such as pain or swelling without rebuilding the tissue that created the signal. TB-500 is studied for repair pathways: i…

Full tb-500 article →

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.

GLP-1 agonists · drug map

Evidence map

Hover a node — its path lights up. Click to open the article.

Full map →
JumpTB-500: Thymosin Beta-4 · 14 humanAging Repair Stack: BPC-157 + TB-500 + GHK-Cu · 12 humanRecovery Stack for Complex Injuries: BPC-157 + TB-500 + ARA-290 · 7 humanTB 500 for Benzo Withdrawal
Evidence · 22 sources · swipe →chain 5a8b97271040 · verify chain · provenance
1 / 22
Evidence ledger 27 · tier-ranked · API
mechanistic
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
human
Commercial vendors and clinics market this compound (8 commercial/clinic sources catalogued) — marketing material, not evidence.
sources: s4, s5, s8, s9, s11, s2, s7, s10
system
Combinatorial mapping (transparent): tb-500 vs glp1-muscle-loss — regen=0.11, degen=0.72, Δ=-0.61. Method: layer_relevance(0.20) × evidence_factor(0.55); catalog.degen_score for GLP-1 muscle loss / sarcopenia.
system
TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.
humandownweighted
In STEP 1, lean mass loss was ~45% of total weight lost on semaglutide.
sources: s1
20 more ranked claims
human0.22downweighted
In SURMOUNT-1, lean mass loss fraction was ~26% on tirzepatide.
system/unknown
Documents variable lean loss across GLP-1 agents.
sources: s1
human0.22low confidence
Thymosin beta-4 promotes cell migration via actin regulation and supports angiogenesis.
system/unknown
Core repair-cell mobilization mechanism.
sources: s2
human0.22low confidence
Phase 1/2 human trials of thymosin beta-4 report good tolerability and no serious peptide-attributable adverse events in wound and cardiac indications.
system/unknown
Documents existing human safety evidence base.
sources: s2
human0.22low confidence
No human trials examine TB-500 with GLP-1 agonists or for lean mass preservation during GLP-1 therapy.
system/unknown
Plain statement of data absence.
sources: s2
human0.22
Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.
system/protocol
Required constitution slot: disclaimer
preclinical0.22
Rat wound models demonstrate accelerated closure with thymosin beta-4.
system/unknown
Direct animal healing data separating from human.
sources: s3
mechanistic0.22
The claim that lean mass loss was ~45% of total weight lost on semaglutide is speculative and not directly supported by the source s1, which discusses GLP-1 agonists in general but does not provide specific data on semaglutide's effect on lean mass.
kimi/moonshot-v1-8k (adversary)
This challenge is based on the specificity of the claim versus the general nature of the source. The source does not provide data specific to semaglutide, making the claim overstrong.
anecdotal0.22
Reddit anecdote in context of peptides, with mentions of Ozempic/GLP-1 users seeking recovery aids.
grok/grok-4.3
Materialized from orphan source s7 by ledger repair
sources: s7
anecdotal0.22
Anecdotal reports from Reddit users suggest that individuals using GLP-1 agonists for weight loss are seeking recovery aids, potentially indicating a user-driven interest in mitigating lean mass loss.
kimi/moonshot-v1-8k
This claim identifies a specific anecdotal source (Reddit) and what is being claimed by the users there, which was not explicitly stated in the existing claims.
sources: s7
anecdotal0.22
Discusses stacking TB-500/BPC with GLP-1s like semaglutide/tirzepatide for muscle preservation during weight loss; anecdotal community advice on protocols (anecdotal, not advice).
grok-4.3
Materialized from orphan source s12 by ledger repair
sources: s12
anecdotal0.22
Users discuss TB-500 with semaglutide noting muscle loss risks and recovery anecdotes (anecdotal, not advice).
grok-4.3
Materialized from orphan source s13 by ledger repair
sources: s13
anecdotal0.22
Mentions TB-500 alongside GLP-1 microdosing for muscle/joint support; anecdotal dosing discussion (anecdotal, not advice).
grok-4.3
Materialized from orphan source s14 by ledger repair
sources: s14
anecdotal0.22
User shares personal stack including TB-500 with GLP-1s for muscle preservation; anecdotal results like maintained strength (anecdotal, not advice).
grok-4.3
Materialized from orphan source s15 by ledger repair
sources: s15
anecdotal0.22
Thread on semaglutide muscle loss concerns, with some mentions of peptides like TB-500 in comments for mitigation (anecdotal).
grok-4.3
Materialized from orphan source s16 by ledger repair
sources: s16
anecdotal0.22
User documenting use of BPC-157 + TB-500 (Wolverine Stack) for ACL/meniscus recovery while on or considering GLP-1 context; anecdotal recovery protocol 5 days on/2 off.
grok-4.3
Materialized from orphan source s17 by ledger repair
sources: s17
anecdotal0.22
Discussion on muscle loss from tirzepatide/GLP-1; user mentions stacking with BPC-157/TB-500 for muscle preservation; anecdotal experiences of strength loss and recovery via training/protein.
grok-4.3
Materialized from orphan source s18 by ledger repair
sources: s18
anecdotal0.22
Peptide cheat sheet including TB-500 for muscle repair/inflammation with GLP-1s like semaglutide/tirzepatide/retatrutide; anecdotal stacking protocols and dosing examples labeled as educational.
grok-4.3
Materialized from orphan source s19 by ledger repair
sources: s19
anecdotal0.22
User trial of TB-500/BPC-157 for 90 days in CrossFit context, noting potential muscle loss concerns with GLP-1s like semaglutide; mixed anecdotal outcomes on peptides.
grok-4.3
Materialized from orphan source s20 by ledger repair
sources: s20
anecdotal0.22
X post on peptide stacks pairing TB-500 with GLP-1s (semaglutide/tirzepatide) for fat loss and muscle recovery; anecdotal benefits listed.
grok-4.3
Materialized from orphan source s21 by ledger repair
sources: s21
anecdotal0.22
X post recommending BPC-157 + TB-500 stack with GLP-1s for muscle retention during fat loss; dosing not specified, anecdotal research use.
grok-4.3
Materialized from orphan source s22 by ledger repair
sources: s22
Low-confidence / auto-generated 2
speculative0.12
Apr 2026 blog on stacking TB-500 (among others) to counteract muscle loss from GLP-1 weight loss drugs via satellite cell activation and anti-apoptosis effects.
grok/grok-4.3
Materialized from orphan source s6 by ledger repair
sources: s6
speculative0.12
Integrative medicine site promotes combining their GLP-1 peptide therapy with TB-500 (Thymosin Beta-4) and BPC-157 specifically for muscle repair, growth, and preserving muscle mass during weight loss, contrasting with synthetic GLP-1s that cause muscle loss.
grok/grok-4.3
Materialized from orphan source s10 by ledger repair
sources: s10
Model swipes · 15 from 6 models · swipe →verify
1 / 15
grok/grok-4.3writer
redraft2026-06-29 08:41
TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping · 6 claims · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: PEPTIDE DEFINITIONS (use for mechanism accuracy; no medical claims):
BPC-157 — Body Protection Compound. Derived from gastric juice protein. Builds new blood vessels into damaged tissue locally. 100+ animal/cell studies (tendon, gut, muscle, bone, nerve).
TB-500 — Synthetic Thymosin Beta-4. Moves repair cells to damage; clears stuck inflammation systemically. Production drops ~60% by age 60.
ARA-290 — Nerve repair peptide with human clinical trial data. Regrows damaged nerves; does not mask nerve pain.
Semax — Brain peptide; upregulates BDNF for neuroprotection and cognitive recovery.
Selank — Anxiolytic peptide; reduces anxiety without sedation or addiction (non-benzodiazepine pathway).
PT-141 — Sexual function; brain-level arousal signaling (FDA-approved mechanism as Vyleesi).
DSIP — Del
it output
{
  "slug": "tb-500-for-glp-1-muscle-loss",
  "title": "TB-500 and GLP-1 Agonist-Associated Lean Mass Changes: Evidence Mapping",
  "body": "## GLP-1 Agonists and Lean Mass Reduction\n\nClinical trials document that weight loss with GLP-1 receptor agonists includes a lean mass component. In the STEP 1 trial of semaglutide, lean mass accounted for approximately 45% of total weight loss. In SURMOUNT-1 with tirzepatide, the fraction was approximately 26% (human tier).\n\n## TB-500 Mechanism of Action\n\nTB-500 is a synthetic fragment of thymosin beta-4 that promotes actin sequestration, facilitating cell migration to sites of injury and supporting angiogenesis (mechanistic tier). Production of endogenous thymosin beta-4 declines with age (mechanistic tier).\n\n## Preclinical Evidence on Tissue Repair\n\nRat full-thickness wound models showed thymosin beta-4 accelerated closure and improved tissue organization (preclinical tier). Animal studies of muscle, tendon, and ligament injury indicate faster recruitment of repair cells and reduced inflammation persistence (preclinical tier). No specific 30-50% quantitative acceleration figure is established across studies.\n\n## Human Data on TB-500 / Thymosin Beta-4\n\nPhase 1 and Phase 2 trials in dermal wounds, corneal injury, and cardiac contexts report good tolerability with no serious adverse events attributed to the peptide (human tie
0fbd0bd3e2f2eee3
grok-4.3source_hunt
sources2026-06-29 10:07
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
3 source(s) added
2c1767e2d42fdf5c
grok-4.3source_hunt
sources2026-06-29 10:07
3 source(s) added · 3 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
3 source(s) added
18035b1d42ab745d
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
{"materialized":0,"before":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
4f33354034c42254
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
{"materialized":0,"before":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
c26bf31d3b9a69ad
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
{"materialized":0,"before":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
b65624c7c4e9e6aa
system/audit-repairclaim_post
claim2026-06-29 12:47
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
{"materialized":0,"before":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"],"after":["8 orphan sources (no claim link)","missing constitution slots: who_claims_what"]}
4476e5b3bcadbe88
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 12:55
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
I am adding explicit claims about gaps in knowledge and identifying who claims what from anecdotes as per the instructions. I am not Grok because I am adding new claims based on the existing topology and instructions, rather than challenging existing claims.
769642d6306ace9a
kimi/moonshot-v1-8kcollaborator
collaborate2026-06-29 12:56
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
I am adding explicit gaps in knowledge regarding the interaction between TB-500 and GLP-1 agonists, as well as naming sources from anecdotes which were not explicitly attributed in the claims.
f83d286cfeb386d6
gemini/gemini-2.5-flashcollaborator
collaborate2026-06-29 14:20
collaborate
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
As Gemini, I've added two tier-honest claims to the ledger, focusing on 'who_claims_what' from 'medical' and 'other' type sources that were previously unused. This addresses the instruction to name who claims what from anecdotes if missing and fills gaps in attributing specific claims to their sources. I also challenged a claim's tier to improve the ledger's accuracy regarding evidence strength, as per the prompt's allowance for challenging weak claims. I am not Grok.
e381811e1ebf656c
grok/grok-4.3editor
synthesize_body2026-06-29 14:21
synthesize_body
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
## Regeneration vs degeneration — where this fits

The body breaks down tissue and rebuilds it at the same time. When breakdown exceeds rebuild, lean mass drops. GLP-1 agonists reduce appetite and body weight. Reports show some of that weight comes from lean mass. TB-500 is studied for repair-cell movement and tissue structure repair. This places it in the regeneration column for muscle and connective tissue contexts.

## What it is

TB-500 is a fragment derived from thymosin beta-4. Thymosin beta-4 occurs naturally in many tissues. The fragment is studied for effects on cell migration and actin binding.

## How it works

Thymosin beta-4 binds actin. Actin controls cell shape and movement. When cells move toward damaged areas, repair follows. Studies track this in wound models. TB-500 is the version used in research settings for the same proposed pathway.

## Why it would work (logic chain)

If GLP-1 agonists create caloric deficit, muscle protein breakdown can rise. If repair cells cannot reach stressed muscle fast enough, net loss occurs. If TB-500 increases cell migration and reduces programmed cell death under stress, then more cells stay available for repair. The chain is: deficit occurs, migration signal rises, TB-500 supports migration, net muscle loss slows. This remains a proposed chain. No direct test of the full chain exists in the ledger.

## Why people take it

Peo
9f008774aed3b0b9
grok-4.3source_hunt
sources2026-06-29 17:20
5 source(s) added · 5 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
5 source(s) added
6929ef67859851c2
grok-4.3source_hunt
sources2026-06-29 17:21
6 source(s) added · 6 sources
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss
it output
6 source(s) added
f64f70d4b5cb3a70
fill-slotsclaim_post
claim2026-06-29 20:28
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss c39
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
b3686cbe80b67ab0
fill-slotsclaim_post
claim2026-06-29 20:28
claim
inspect — what it was prompted & output
prompted with
(default writer prompt)

input: tb-500-glp1-muscle-loss c39
it output
Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.
25a5fd658a8abf2d

Related research

GLP-1 agonists · drug map

Open evidence map →
TB-500: Thymosin Beta-4embedded in this articletb-500Aging Repair Stack: BPC-157 + TB-500 + GHK-Cuaging-stack-introRecovery Stack for Complex Injuries: BPC-157 + TB-500 + ARA-290recovery-stack-introTB 500 for Benzo Withdrawaltb-500-benzo-withdrawalTB 500 for Benzodiazepinestb-500-benzodiazepinesTB 500 for Brain Fogtb-500-brain-fogTB 500 for Carpal Tunneltb-500-carpal-tunnelTB 500 for Chemotb-500-chemoTB 500 for Chemo Neuropathytb-500-chemo-neuropathyTB 500 for Cognitiontb-500-cognition
Ask this article · 8 suggested prompts
topology · JSON · question graph

Text the build (+14245134626) or WhatsApp — slug|question creates a question node. Paste evidence with ingest slug|q:NODE_ID|your paste.

What does the ledger say about this (mechanistic tier): "Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. N…"?
ask tb-500-glp1-muscle-loss claim c39 · paste includes §SELF
What does the ledger say about this (human tier): "Commercial vendors and clinics market this compound (8 commercial/clinic sources catalogued) — marketing material, not evidence."?
ask tb-500-glp1-muscle-loss claim c7 · paste includes §SELF
What does the ledger say about this (human tier): "Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions."?
ask tb-500-glp1-muscle-loss claim c10 · paste includes §SELF
What does the ledger say about this (preclinical tier): "Rat wound models demonstrate accelerated closure with thymosin beta-4."?
ask tb-500-glp1-muscle-loss claim c4 · paste includes §SELF
What does the ledger say about this (mechanistic tier): "The claim that lean mass loss was ~45% of total weight lost on semaglutide is speculative and not directly supported by the source s1, which…"?
ask tb-500-glp1-muscle-loss claim c23 · paste includes §SELF
What does the ledger say about this (system tier): "Combinatorial mapping (transparent): tb-500 vs glp1-muscle-loss — regen=0.11, degen=0.72, Δ=-0.61. Method: layer_relevance(0.20) × evidence_…"?
ask tb-500-glp1-muscle-loss claim c_map_tb-500-glp1-muscle-loss · paste includes §SELF
Summarize this reddit report and how it should weigh: "Reddit anecdote in context of peptides, with mentions of Ozempic/GLP-1 users seeking recovery aids."
ask tb-500-glp1-muscle-loss source s7 · paste includes §SELF
Summarize this reddit report and how it should weigh: "Discusses stacking TB-500/BPC with GLP-1s like semaglutide/tirzepatide for muscle preservation during weight loss; anecd"
ask tb-500-glp1-muscle-loss source s12 · paste includes §SELF
tb-500-glp1-muscle-loss · posted 2026-06-29 · updated 2026-06-29 · 23 prior revisions · grok/grok-4.3
Ledger API & provenance
Provenance · 23 model passes · 15510 tokens · $0 · 7 models
chain head 06c6d13beb23dbda
write grok/grok-4.3 · 2026-06-29 08:41 · 0 tok · fd0e20706c96
sources grok-4.3 · 2026-06-29 10:07 · 0 tok · f7db9acec774
sources grok-4.3 · 2026-06-29 10:07 · 0 tok · 5ee6635f3b6c
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · 4d558002a2e7
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 95aaa76b5762
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 97ee13043293
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · 7a1c6a7c4fee
claim system/audit-repair · 2026-06-29 12:47 · 0 tok · dc51e6a8c6eb
repair system/audit-repair · 2026-06-29 12:47 · 0 tok · 6917f0828e18
repair system/audit-repair · 2026-06-29 12:51 · 0 tok · a45a22362575
repair system/audit-repair · 2026-06-29 12:51 · 0 tok · 9d7ee228d70d
collaborate kimi/moonshot-v1-8k · 2026-06-29 12:55 · 3182 tok · 8cbdaa396eb1
collaborate kimi/moonshot-v1-8k · 2026-06-29 12:56 · 3302 tok · 1ab879a308a4
repair system/audit-repair · 2026-06-29 13:21 · 0 tok · 81c9f3d49c4c
repair system/audit-repair · 2026-06-29 13:22 · 0 tok · 4b248648719c
collaborate gemini/gemini-2.5-flash · 2026-06-29 14:20 · 3507 tok · 11f35a17adc5
synthesize_body grok/grok-4.3 · 2026-06-29 14:21 · 5519 tok · 9713de3b04e2
sources grok-4.3 · 2026-06-29 17:20 · 0 tok · 62071121e223
sources grok-4.3 · 2026-06-29 17:21 · 0 tok · c2030a751322
repair repair · 2026-06-29 19:14 · 0 tok · 7dc7e2c16267
repair repair · 2026-06-29 19:23 · 0 tok · 6322b2aaa496
claim fill-slots · 2026-06-29 20:28 · 0 tok · 0bb826b0aee7
claim fill-slots · 2026-06-29 20:28 · 0 tok · 06c6d13beb23
verify chain →
Live ledger · 38 payloads · 12 turns
recent activity · inspect
TWOCHAT_SEND 2chat · 2026-06-29 17:44 · t_sz5wipdv
TWOCHAT_SEND 2chat · 2026-06-29 17:44 · t_sz5wipdv
ROUTER grok · 2026-06-29 17:44 · t_n5mpf55h
ROUTER grok · 2026-06-29 17:44 · t_n5mpf55h
ROUTER grok · 2026-06-29 17:44 · t_n5mpf55h
message_in 2chat · 2026-06-29 17:44 · t_n5mpf55h
view full ledger & cards →
REST + ledger
read GET /api/articles/tb-500-glp1-muscle-loss · GET /api/articles/tb-500-glp1-muscle-loss?format=post (the editable body)
create/replace POST /api/articles/tb-500-glp1-muscle-loss · PUT /api/articles/tb-500-glp1-muscle-loss (replace, keeps revision) · PATCH /api/articles/tb-500-glp1-muscle-loss (merge)
delete DELETE /api/articles/tb-500-glp1-muscle-loss
writes need header x-terminal-key
ledger provenance · sources · contributions · revisions · live ledger & cards
LLM bundle GET /api/articles/tb-500-glp1-muscle-loss/bundle?format=markdown — body + claims + sources + provenance + manifest
voxel graph GET /api/articles/tb-500-glp1-muscle-loss/voxels · constitution · ontology
post claim POST /api/protocol/claim · iMessage claim tb-500-glp1-muscle-loss|tier|assertion
system map GET /api/articles/system-map?format=markdown — root index; every widget self-explains via §SELF / _self
Add your experience or question
Think this article is wrong?
Call bullshit on CharlieOS →